Wu, J.T.; Cheuk, A.; Isanogle, K.; Robinson, C.; Zhang, X.; Ceribelli, M.; Beck, E.; Shinn, P.; Klumpp-Thomas, C.; Wilson, K.M.;
et al. Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma. Cancers 2023, 15, 4034.
https://doi.org/10.3390/cancers15164034
AMA Style
Wu JT, Cheuk A, Isanogle K, Robinson C, Zhang X, Ceribelli M, Beck E, Shinn P, Klumpp-Thomas C, Wilson KM,
et al. Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma. Cancers. 2023; 15(16):4034.
https://doi.org/10.3390/cancers15164034
Chicago/Turabian Style
Wu, Jerry T., Adam Cheuk, Kristine Isanogle, Christina Robinson, Xiaohu Zhang, Michele Ceribelli, Erin Beck, Paul Shinn, Carleen Klumpp-Thomas, Kelli M. Wilson,
and et al. 2023. "Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma" Cancers 15, no. 16: 4034.
https://doi.org/10.3390/cancers15164034
APA Style
Wu, J. T., Cheuk, A., Isanogle, K., Robinson, C., Zhang, X., Ceribelli, M., Beck, E., Shinn, P., Klumpp-Thomas, C., Wilson, K. M., McKnight, C., Itkin, Z., Sotome, H., Hirai, H., Calleja, E., Wacheck, V., Gouker, B., Peer, C. J., Corvalan, N.,
... Khan, J.
(2023). Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma. Cancers, 15(16), 4034.
https://doi.org/10.3390/cancers15164034